Subscribe To
KRON / Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 31% in 4 Weeks
KRON News
By Zacks Investment Research
May 10, 2023
Kronos Bio, Inc. (KRON) Reports Q1 Loss, Misses Revenue Estimates
Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to los more_horizontal
By Market Watch
January 9, 2023
Kronos Bio's stock rallies after announcing drug-discovery deal with Roche
Shares of Kronos Bio Inc. KRON, +2.38% jumped 25% in premarket trading on Monday after the company announced a development deal with Roche Holding's R more_horizontal
By Zacks Investment Research
December 12, 2022
Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 31% in 4 Weeks
Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined wit more_horizontal
By Zacks Investment Research
November 22, 2022
Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 23.8% in 4 Weeks
Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined wit more_horizontal
By GlobeNewsWire
June 1, 2022
Kronos Bio Announces Participation in Upcoming Investor Conferences
SAN MATEO, Calif. and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the liv more_horizontal